GI Innovation registers patent in US for its GI-101/GI-102

For their combined use with other drugs to treat cancer

Expectations rise on their use as combinations to extend patents for blockbuster anticancer drugs that are ahead of patent expiry

GI Innovation R&D center researchers are researching formulation and synthesis.

GI Innovation announced on the 15th that it had registered patents for its immune-oncology drug GI-101/GI-102 in combination with various anticancer drugs.

 

The company registered the patent for 101/GI-102 for broad application with global blockbuster anticancer drugs such as PARP inhibitors, CDK4/6 inhibitors, and VEGFR inhibitors, allowing it to enjoy exclusive rights as combination therapy with various anticancer drugs in the registered class.

 

In May, the company had previously secured exclusive rights in the US for the use of GI-101 or GI-102 in combination with PD-1 antibodies like Keytruda, and PDL1 antibodies like atezolizumab by registering a patent for their combined use with these immunotherapies.

 

The anticancer drug combination therapy patent registered this time includes exclusive rights for GI-101 or GI-102’s use as combination therapy with various anticancer drugs, including PARP inhibitors, CDK4/6 inhibitors, VEGFR inhibitors, and EGFR inhibitors.

 

Therefore, the patent is expected to provide comprehensive protection.

 

In addition, it can serve as a partner for blockbuster anticancer drugs seeking patent term extensions.

 

According to the global market research institution Research Nester, the substance patent term for abemaciclib (patent set to expire in 2029), which owns the largest share of the KRW 2.5 trillion CDK 4/6 inhibitor market, and Olaparib (patent set to expire in 2028) that post the largest amount of sales in the PARP inhibitor market, is set to soon expire.

 

In this context, GI Innovation secured a patent on their combined use with GI-101 and GI-102 that lasts until 2041.

 

Therefore, based on this registered patent, the companies can adopt a drug approval strategy, developing a co-formulation with blockbuster anticancer drugs and conducting clinical trials on combination therapies for an evergreen effect.

 

Myung-Ho Jang, CSO of New Drug Development and Clinical Trial and the inventor of the patent said, “The patent we recently registered in the US is as combination therapy with blockbuster anticancer drugs whose patents are about to expire, demonstrating sufficient value as a partner for use in combination with various anticancer drugs depending on the clinical results.

 

We plan to discuss further plans with global pharmaceutical companies next year to license out our technology.”